Anti-Hu C3b/iC3b Alexa Fluor® 647

*Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP: Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol. 2007 Sep 15;179 (6) :4263-71. , URL: https://pubmed.ncbi.nlm.nih.gov/17785867/, *Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP: An anti-C3b (i) mAb enhances complement activation, C3b (i) deposition, and killing of CD20+ cells by rituximab. 2003 Feb 1;101 (3) :1071-9., URL: https://pubmed.ncbi.nlm.nih.gov/12393727/, *Pokrass MJ, Liu MF, Lindorfer MA, Taylor RP: Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy. Mol Immunol. 2013 Dec;56 (4) :549-60., URL: https://pubmed.ncbi.nlm.nih.gov/23911412/, *DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP: Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol Immunol. 2006 Mar;43 (7) :1010-9., URL: https://pubmed.ncbi.nlm.nih.gov/15961157/, *Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ: A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 2010 Mar 18;115 (11) :2283-91., URL: https://pubmed.ncbi.nlm.nih.gov/20068220/